Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma

Cancers, Год журнала: 2023, Номер 15(3), С. 830 - 830

Опубликована: Янв. 29, 2023

Glioblastoma, a WHO grade IV astrocytoma, constitutes approximately half of malignant tumors the central nervous system. Despite technological advancements and aggressive multimodal treatment, prognosis remains dismal. The highly vascularized nature glioblastoma enables tumor cells to grow invade surrounding tissue, vascular endothelial growth factor-A (VEGF-A) is critical mediator this process. Therefore, over past decade, angiogenesis, more specifically, VEGF signaling pathway, has emerged as therapeutic target for therapy. This led FDA approval bevacizumab, monoclonal antibody designed against VEGF-A, treatment recurrent glioblastoma. promising preclinical data its theoretical effectiveness, bevacizumab failed improve patients’ overall survival. Furthermore, several other anti-angiogenic agents that pathway have also not demonstrated survival improvement. suggests presence compensatory angiogenic pathways surpass effects these facilitate vascularization despite ongoing inhibition. Herein, we review current state agents, discuss potential mechanisms resistance, suggest avenues increase efficacy approach.

Язык: Английский

---

Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma

Pharmaceutics, Год журнала: 2023, Номер 15(3), С. 928 - 928

Опубликована: Март 13, 2023

Glioblastoma multiforme (GBM) remains a challenging disease, as it is the most common and deadly brain tumour in adults has no curative solution an overall short survival time. This incurability time means that, despite its rarity (average incidence of 3.2 per 100,000 persons), there been increased effort to try treat this disease. Standard care newly diagnosed glioblastoma maximal resection followed by initial concomitant radiotherapy temozolomide (TMZ) then further chemotherapy with TMZ. Imaging techniques are key not only diagnose extent affected tissue but also for surgery planning even intraoperative use. Eligible patients may combine TMZ treating fields (TTF) therapy, which delivers low-intensity intermediate-frequency electric arrest growth. Nonetheless, blood–brain barrier (BBB) systemic side effects obstacles successful GBM; thus, more targeted, custom therapies such immunotherapy nanotechnological drug delivery systems have undergoing research varying degrees success. review proposes overview pathophysiology, possible treatments, (not all) representative examples latest advancements.

Язык: Английский

---

The Promise of Niacin in Neurology

Neurotherapeutics, Год журнала: 2023, Номер 20(4), С. 1037 - 1054

Опубликована: Апрель 21, 2023

Язык: Английский

---

METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling

Cell Death and Disease, Год журнала: 2023, Номер 14(7)

Опубликована: Июль 12, 2023

Abstract Long noncoding RNAs (lncRNAs) are involved in glioma initiation and progression. Glioma stem cells (GSCs) essential for tumor initiation, maintenance, therapeutic resistance. However, the biological functions underlying mechanisms of lncRNAs GSCs remain poorly understood. Here, we identified that LINC00839 was overexpressed GSCs. A high level associated with GBM progression radiation METTL3-mediated m6A modification on enhanced its expression a YTHDF2-dependent manner. Mechanistically, functioned as scaffold promoting c-Src-mediated phosphorylation β-catenin, thereby inducing Wnt/β-catenin activation. Combinational use celecoxib, an inhibitor signaling, greatly sensitized to radiation. Taken together, our results showed LINC00839, modified by m6A, exerts resistance activating signaling.

Язык: Английский

---

Cannabidiol induces ERK activation and ROS production to promote autophagy and ferroptosis in glioblastoma cells

Chemico-Biological Interactions, Год журнала: 2024, Номер 394, С. 110995 - 110995

Опубликована: Апрель 5, 2024

Язык: Английский

---